- Home
- EQC vs MYGN Comparison
EQC vs MYGN Comparison
Compare EQC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQC
- MYGN
- Stock Information
- Founded
- EQC 1986
- MYGN 1991
- Country
- EQC United States
- MYGN United States
- Employees
- EQC N/A
- MYGN N/A
- Industry
- EQC Real Estate Investment Trusts
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EQC Real Estate
- MYGN Health Care
- Exchange
- EQC Nasdaq
- MYGN Nasdaq
- Market Cap
- EQC 2.2B
- MYGN 2.0B
- IPO Year
- EQC 1986
- MYGN 1995
- Fundamental
- Price
- EQC $1.74
- MYGN $13.17
- Analyst Decision
- EQC
- MYGN Hold
- Analyst Count
- EQC 0
- MYGN 12
- Target Price
- EQC N/A
- MYGN $23.92
- AVG Volume (30 Days)
- EQC 5.4M
- MYGN 905.1K
- Earning Date
- EQC 02-10-2025
- MYGN 11-07-2024
- Dividend Yield
- EQC N/A
- MYGN N/A
- EPS Growth
- EQC N/A
- MYGN N/A
- EPS
- EQC 0.38
- MYGN N/A
- Revenue
- EQC $58,433,000.00
- MYGN $823,600,000.00
- Revenue This Year
- EQC N/A
- MYGN $13.82
- Revenue Next Year
- EQC N/A
- MYGN $4.59
- P/E Ratio
- EQC $4.52
- MYGN N/A
- Revenue Growth
- EQC N/A
- MYGN 12.15
- 52 Week Low
- EQC $1.40
- MYGN $12.87
- 52 Week High
- EQC $21.00
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- EQC 4.79
- MYGN 23.34
- Support Level
- EQC $1.66
- MYGN $13.92
- Resistance Level
- EQC $1.76
- MYGN $15.44
- Average True Range (ATR)
- EQC 0.11
- MYGN 0.85
- MACD
- EQC -1.17
- MYGN -0.03
- Stochastic Oscillator
- EQC 1.78
- MYGN 7.58
About EQC Equity Commonwealth of Beneficial Interest
Equity Commonwealth is a real estate investment trust engaged in the acquisition, ownership, and operation of office buildings located throughout the United States. The vast majority of the company's real estate portfolio comprises office assets. These properties are fairly evenly dispersed between many of America's urban markets, notably Washington, Austin, and Denver. Equity Commonwealth derives the vast majority of its income in the form of rental revenue from tenants occupying its offices.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.